Brought to you by 
Vifor invests $50mm in Akebia; gets rights to distribute vadadustat to Fresenius dialysis centers
22 Feb 2022
Executive Summary
Akebia Therapeutics Inc. granted Vifor Pharma Group rights to exclusively distribute its anemia treatment vadadustat to Fresenius Medical Care North America dialysis centers (specifically, Fresenius Kidney Care LLC), once the candidate is approved by the FDA. Under terms of the deal, Vifor made a $50mm equity investment in Akebia through the purchase of 3.57mm common shares at $14 (an 11% premium).
Deal Industry
- Biotechnology
- Pharmaceuticals
- Services
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vifor invests $50mm in Akebia; gets rights to distribute vadadustat to Fresenius dialysis centers
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice